These data correlate with the observation that nuclear immunoreactivity of the Ki67 cell proliferating marker (Fig. 7 panel C) markedly decreases after A-EMHVs-MF treatment (6.5% positive nuclei of a total nuclear count of 572 cells) as compared to CTRL and A2 (20.3% and 16.8% positive nuclei, respectively), suggesting that A-EMHVs-MF hampers cell replicating activity within tumour mass. This evidence concerns the gene MKI67 and neoplasm.